Clinical trials: Anti-PD-L1 Antibody
Esophageal Neoplasms
Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer
The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced…
- Trial name
- AIPAAIAEC (NCT05349045)
- Testing
- an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Solid Tumor
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors
This early phase, multicenter, open-label, single-arm study evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of atezolizumab in pediatric and young adult participants with solid…
- Trial name
- NCT02541604
- Testing
- Atezolizumab
- Where
- 30 sites in United States, Canada and 9 more
- Volunteers
- 87 people
- Sponsor
- Hoffmann-La Roche
T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory
Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma
The AVAIL-T trial is a trial to find out how effective avelumab is at treating patients with primary T-cell lymphoma that is refractory to or has relapsed following initial treatment.
- Trial name
- AVAIL-T (NCT03046953)
- Testing
- Avelumab
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- University of Birmingham
Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma
This phase II trial studies how well atezolizumab or atezolizumab plus bevacizumab works in treating patients with alveolar soft part sarcoma that has not been treated, has spread from where it started to other places in the body…
- Trial name
- NCT03141684
- Testing
- Atezolizumab, Bevacizumab, Biospecimen Collection
- Where
- 42 sites in United States
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
This phase II trial studies how well atezolizumab works in treating patients with chondrosarcoma or clear cell sarcoma that is newly diagnosed, cannot be removed by surgery (unresectable), or has spread to other places in the…
- Conditions
- Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT04458922
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 15 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer
An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer
This exploratory clinical study evaluates the efficacy and safety of combining benmelstobart (a PD-L1 inhibitor) with anlotinib (a multi-target anti-angiogenic TKI) as a first-line, chemotherapy-free treatment for elderly…
- Conditions
- Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
- Trial name
- BEACON-OLD (NCT07849712)
- Testing
- Benmelstobart Combined With Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
High-grade Osteosarcoma
Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy
It is a randomized, double-blind, placebo-controlled, multicenter study with the sample size is 362. The patients with high-grade osteosarcoma who had previously received surgery and completed adjuvant chemotherapy will be…
- Trial name
- NCT04359550
- Testing
- Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
- Volunteers
- 362 people
- Sponsor
- Lee's Pharmaceutical Limited
NSCLC (Advanced Non-small Cell Lung Cancer)
A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This is a Randomized, Double-Blind, Multicenter, Phase II/III Study to Evaluate HLX37 (Recombinant Human Anti-PD-L1 and Anti-VEGF Bispecific Antibody) in Combination with Chemotherapy Versus Pembrolizumab in Combination with…
- Trial name
- NCT07865910
- Testing
- Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion)
- Where
- 16 sites in China
- Volunteers
- 1,438 people
- Sponsor
- Shanghai Henlius Biotech